BNTC vs. ETNB, ADPT, EVO, SPRY, ARDX, OCUL, GPCR, CALT, IOVA, and SNDX
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include 89bio (ETNB), Adaptive Biotechnologies (ADPT), Evotec (EVO), ARS Pharmaceuticals (SPRY), Ardelyx (ARDX), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Calliditas Therapeutics AB (publ) (CALT), Iovance Biotherapeutics (IOVA), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.
Benitec Biopharma vs.
Benitec Biopharma (NASDAQ:BNTC) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
Benitec Biopharma has higher revenue and earnings than 89bio. Benitec Biopharma is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Benitec Biopharma had 5 more articles in the media than 89bio. MarketBeat recorded 11 mentions for Benitec Biopharma and 6 mentions for 89bio. Benitec Biopharma's average media sentiment score of 0.70 beat 89bio's score of 0.52 indicating that Benitec Biopharma is being referred to more favorably in the media.
Benitec Biopharma has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, 89bio has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.
Benitec Biopharma's return on equity of -44.61% beat 89bio's return on equity.
52.2% of Benitec Biopharma shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 2.8% of 89bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Benitec Biopharma received 82 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 65.55% of users gave Benitec Biopharma an outperform vote while only 63.33% of users gave 89bio an outperform vote.
Benitec Biopharma currently has a consensus target price of $24.43, indicating a potential upside of 74.37%. 89bio has a consensus target price of $27.56, indicating a potential upside of 243.59%. Given 89bio's higher probable upside, analysts clearly believe 89bio is more favorable than Benitec Biopharma.
Summary
Benitec Biopharma beats 89bio on 12 of the 16 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Benitec Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:BNTC) was last updated on 3/27/2025 by MarketBeat.com Staff